Abstract:Abstract Helper CD4+ T cells are key players in the adaptive immune response that differentiate into different subpopulations. One of these subpopulations are T helper 17 (Th17) cells. In cancer, the role of Th17 cells is still controversial. The dual effect that Th17 cells seem to have in cancer can be explained by the great heterogeneity and/or plasticity of these cells. Two different subpopulations of Th17 cells have been reported: regulatory or “non-pathogenic” Th17 cells and effector or “pathogenic” Th17 cells. We currently know that this dual behavior depends on the cytokine microenvironment in which Th17 cells differentiate. However, the molecular basis of how, when, and why Th17 cells differentiate into effector or regulatory populations, as well as its in vivo relevance, are still poorly understood. Here we show that intrinsic expression of TMEM176B can determine the fate of Th17 cells. TMEM176b is a druggable immunoregulatory ion channel which function was first described by our team. We have found that in in vitro differentiated Th17 cells, Tmem176b is over-expressed in regulatory Th17 cells compared to effector Th17 cells, in agreement with its immunoregulatory properties. Furthermore, we found that Tmem176b influence Th17 polarity, since Th17 in vitro differentiation with IL-6+TGF-β from naïve Tmem176b−/− CD4+ T cells results in an enhanced IFN-γ production. Same results were obtained by pharmacological inhibition of TMEM176B in WT CD4+ T cells. Functional evaluation of these cells showed a decreased regulatory capacity compared to WT Th17 cells. Thus, WT Th17 cells inhibited CD8+ T cell proliferation whereas Tmem176b−/− Th17 cells showed poor inhibitory capacity. Supporting this effector-like phenotype, Tmem176b−/− Th17 cells have higher basal pAKT/AKT ratio compared to WT Th17 cells. Furthermore, Tmem176b−/− Th17 cells have a better metabolic fitness than WT Th17 cells, with higher glycolysis and oxidative phosphorylation. It was reported that the effector role of Th17 cells is dependent on the IL-1β production through ASC-NLRP3-caspase 8 activation. Here we show that Tmem176b−/− Th17 cells stimulated with ATP have a higher Caspase-8 activation compared to WT Th17 cells. All these results suggest that Tmem176b deficiency leads to an effector-like Th17 cell phenotype when cells are differentiated in a regulatory cytokine microenvironment. Moreover, co-culture of Tmem176b−/− Th17 cells with in vitro generated exhausted CD8+ T cells results in a reduction of the frequency of terminal exhausted CD8+ T cells and of mitochondrial reactive oxygen species production compared to co-culture with WT Th17 cells. Therefore, Tmem176b−/− Th17 may have enhanced anti-tumor properties compared to WT Th17 cells. In conclusion, we have identified a new intrinsic regulator of Th17 cells, TMEM176B, which may constitute a molecular target to pharmacologically modulate these cells. Citation Format: Sofia Russo, Mateo Malcuori, Mercedes Segovia, Marcelo Hill. Immune and metabolic control of Th17 cells by TMEM176B: Potential implication in cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1412.

RTF1 mediates epigenetic control of Th17 cell differentiation via H2B monoubiquitination

TL1A Modulates the Severity of Colitis by Promoting Th9 Differentiation and IL-9 Secretion.

Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity

TRAF3 regulates the effector function of regulatory T cells and humoral immune responses.

Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-κB/MAPKs Pathway

Nsun2 coupling with RoRγt shapes the fate of Th17 cells and promotes colitis

Rkip Mediates Autoimmune Inflammation By Positively Regulating Il-17r Signaling

Reciprocal Regulation of RORγt Acetylation and Function by P300 and HDAC1

Deubiquitination of aryl hydrocarbon receptor by USP21 negatively regulates T helper 17 cell differentiation

HSF1 promotes CD69+ Treg differentiation to inhibit colitis progression

Cutting Edge: Ubiquitin-Specific Protease 4 Promotes Th17 Cell Function under Inflammation by Deubiquitinating and Stabilizing RORγt

IL-6/STAT3 Pathway Induced Deficiency of RFX1 Contributes to Th17-dependent Autoimmune Diseases Via Epigenetic Regulation.

USP18 inhibits NF-κB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex.

The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells

TSC 1 Regulates the Balance Between Effector and Regulatory T Cells

Deubiquitination of Aryl Hydrocarbon Receptor (ahr) by USP21 Negatively Regulates Th17 Cells Differentiation.

USP1-regulated Reciprocal Differentiation of Th17 Cells and Treg Cells by Deubiquitinating and Stabilizing TAZ.

Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation

Abstract 1412: Immune and metabolic control of Th17 cells by TMEM176B: Potential implication in cancer immunotherapy

FOXP3 exon 2 controls T reg stability and autoimmunity

Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases